Atropine vs MiSight Contact Lenses for Near-Sightedness
Trial Summary
What is the purpose of this trial?
This trial is testing eye drops and special glasses or contact lenses to see if they can slow down worsening nearsightedness in children by controlling eye growth and changing how light enters the eye.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are using any form of myopia control or certain contact lenses, you may not be eligible to participate.
What data supports the effectiveness of the treatment for near-sightedness?
Research shows that using 0.05% atropine eye drops combined with MiSight contact lenses can significantly slow down the progression of near-sightedness in children. In a study, this combination reduced the average myopia progression from -1.45 to -0.41 over one year, indicating its effectiveness in controlling myopia.12345
Is the combination of atropine and MiSight contact lenses safe for treating near-sightedness?
How does the treatment of atropine and MiSight contact lenses for near-sightedness differ from other treatments?
The combination of 0.05% atropine eye drops and MiSight contact lenses is unique because it targets myopia (near-sightedness) progression by using both a pharmacological approach and a specialized contact lens that alters how light focuses on the retina. This dual approach has shown effectiveness in significantly slowing myopia progression in children, which is not typically achieved with standard glasses or contact lenses alone.136910
Eligibility Criteria
This trial is for children aged 5-12 with mild to high near-sightedness, weighing over 1500g at birth and born after at least 32 weeks of gestation. It excludes those with certain eye abnormalities, previous myopia treatments, systemic conditions affecting the eyes, or a history of eye surgeries.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either 0.05% atropine drops or MiSight contact lenses for myopia control
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Atropine (Anticholinergic Agent)
- MiSight contact lenses (Contact Lens)
Atropine is already approved in United States, Canada for the following indications:
- Uveitis
- Pupillary dilation
- Refraction assessment
- Amblyopia
- Cycloplegia
- Uveitis
- Pupillary dilation
- Refraction assessment
- Amblyopia
- Cycloplegia